86 results
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Number | Weighted- Average Exercise Price | Weighted- Average Remaining Term | Aggregate- Intrinsic Value (in 000’s) | |||||||||||
Balance as of December 31, 2023 | 2,813,937 | $ | 4.10 | 7.8 years | $ | 562 | ||||||||
Granted | 1,375,088 | $ | 11.23 | |||||||||||
Exercised | (15,104) | $ | 3.90 | |||||||||||
Forfeited and expired | (4,040) | $ | 4.05 | |||||||||||
Balance as of March 31, 2024 | 4,169,881 | $ | 6.47 | 8.9 years | $ | 33,378 | ||||||||
Vested and expected to vest at March 31, 2024 | 1,096,002 | $ | 4.13 | 7.6 years | $ | 11,086 | ||||||||
Exercisable as of March 31, 2024 | 1,161,181 | $ | 4.20 | 7.7 years | $ | 11,666 |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
As of March 31, 2024 | ||||||||||||||||
Acquisition Cost | Unrealized Gain | Unrealized Loss | Estimated Fair Value | |||||||||||||
Money market funds | $ | 22,546 | $ | — | $ | — | $ | 22,546 | ||||||||
U.S. government obligations | 75,103 | 6 | (27) | 75,082 | ||||||||||||
Corporate debt securities | 4,655 | 1 | (1) | 4,655 | ||||||||||||
Total cash equivalents and investments | $ | 102,304 | $ | 7 | $ | (28) | $ | 102,283 | ||||||||
Classified as: | ||||||||||||||||
Cash equivalents | $ | 22,546 | ||||||||||||||
Short-term investments | 79,737 | |||||||||||||||
Total cash equivalents and investments | $ | 102,283 |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
March 31, | December 31, | |||||||
2024 | 2023 | |||||||
(unaudited) | ||||||||
Lab equipment | $ | 4,368 | $ | 4,264 | ||||
Computers and software | 836 | 833 | ||||||
Leasehold improvements | 46 | 46 | ||||||
Furniture and fixtures | 157 | 157 | ||||||
5,407 | 5,300 | |||||||
Less accumulated depreciation and amortization | 2,989 | 2,727 | ||||||
$ | 2,418 | $ | 2,573 |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Conversion of outstanding convertible preferred stock | 14,740,840 | 14,740,840 | ||||||
Options to purchase common stock | 4,169,881 | 2,813,937 | ||||||
Options early exercised subject to future vesting | 959 | 1,481 | ||||||
Total | 18,911,680 | 17,556,258 |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Research and development expenses | $ | 524 | $ | 272 | ||||
General and administrative expenses | 804 | 343 | ||||||
Total stock-based compensation | $ | 1,328 | $ | 615 |
10-Q
0bp7reb
13 May 24
Quarterly report
7:06am
10-Q
a3l5 jdpzrd
13 May 24
Quarterly report
7:06am
10-Q
h27l5h28
13 May 24
Quarterly report
7:06am
10-Q
pz56sz9qk86
13 May 24
Quarterly report
7:06am
10-Q
o3id9hbicb
13 May 24
Quarterly report
7:06am
10-Q
d2lmzyn 4jlgvl9n3
13 May 24
Quarterly report
7:06am
10-Q
curwudre88 k87v
13 May 24
Quarterly report
7:06am
10-Q
uqt757rma2ivzf9w9
13 May 24
Quarterly report
7:06am
10-Q
wqlwq2k5jqcum7tn tp
13 May 24
Quarterly report
7:06am
10-Q
xgoqgxw
13 May 24
Quarterly report
7:06am
10-Q
7g4xn
13 May 24
Quarterly report
7:06am
10-Q
b9cs8q
13 May 24
Quarterly report
7:06am
10-Q
450hjuj 0n
13 May 24
Quarterly report
7:06am
10-Q
j0a3 10elb5de
13 May 24
Quarterly report
7:06am
10-Q
77g 02ajijh1h
13 May 24
Quarterly report
7:06am